BC Week In Review | Jan 29, 2007
Company News

Acumen Pharmaceuticals, Merck deal

Acumen received a $5 million milestone payment under a 2004 deal that was amended in 2006, which gives MRK exclusive worldwide rights to develop MAbs, vaccines and diagnostics against amyloid-derived diffusible ligand (ADDL) for Alzheimer's...
BC Week In Review | Dec 4, 2006
Company News

Acumen Pharmaceuticals, Merck deal

The companies amended a 2004 agreement, giving MRK exclusive R&D rights to diagnostic products directed at amyloid-derived diffusible ligands (ADDLs). All other rights in the original agreement remain unchanged, including MRK's exclusive worldwide rights to...
BC Week In Review | Jan 19, 2004
Company News

Acumen Pharmaceuticals Inc., Merck deal

Acumen granted MRK exclusive worldwide rights to its amyloid-derived diffusible ligand (ADDL) target for use in developing monoclonal antibodies and vaccines to treat Alzheimer's disease (AD). Acumen will receive upfront and research payments, and is...
BioCentury | Jan 19, 2004
Tools & Techniques

Rogue peptides in Alzheimer's

A number of companies are trying to develop antibodies or vaccines against the plaques seen as crucial for the onset and progression of Alzheimer's disease, but none has been successful so far. Acumen Pharmaceuticals Inc....
BC Extra | Jan 13, 2004
Company News

Acumen, Merck Alzheimer's deal

Acumen Pharmaceuticals (San Francisco, Calif.) granted MRK exclusive worldwide rights to its amyloid-derived diffusible ligand (ADDL) target for use in developing monoclonal antibodies and vaccines to treat Alzheimer's disease (AD). Acumen will receive upfront and...
BC Week In Review | Jun 1, 1998
Company News

Northwestern University other research news

Northwestern researchers and colleagues published in the Proceedings of the National Academy of Sciences an association between a new form of the amyloid beta protein, called amyloid beta-derived diffusible ligands, and the impaired neuronal function...
Items per page:
1 - 6 of 6